PL3143025T3 - Związki do leczenia rdzeniowego zaniku mięśni - Google Patents
Związki do leczenia rdzeniowego zaniku mięśniInfo
- Publication number
- PL3143025T3 PL3143025T3 PL15721701T PL15721701T PL3143025T3 PL 3143025 T3 PL3143025 T3 PL 3143025T3 PL 15721701 T PL15721701 T PL 15721701T PL 15721701 T PL15721701 T PL 15721701T PL 3143025 T3 PL3143025 T3 PL 3143025T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993839P | 2014-05-15 | 2014-05-15 | |
| PCT/EP2015/060343 WO2015173181A1 (en) | 2014-05-15 | 2015-05-11 | Compounds for treating spinal muscular atrophy |
| EP15721701.9A EP3143025B1 (en) | 2014-05-15 | 2015-05-11 | Compounds for treating spinal muscular atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3143025T3 true PL3143025T3 (pl) | 2020-03-31 |
Family
ID=53175048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15721701T PL3143025T3 (pl) | 2014-05-15 | 2015-05-11 | Związki do leczenia rdzeniowego zaniku mięśni |
| PL19200058.6T PL3663296T3 (pl) | 2014-05-15 | 2015-05-11 | Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19200058.6T PL3663296T3 (pl) | 2014-05-15 | 2015-05-11 | Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9969754B2 (pl) |
| EP (3) | EP3663296B1 (pl) |
| JP (1) | JP6236173B2 (pl) |
| KR (2) | KR102213740B1 (pl) |
| CN (1) | CN106459092B (pl) |
| AR (1) | AR100442A1 (pl) |
| AU (1) | AU2015261046C1 (pl) |
| CA (1) | CA2948561C (pl) |
| CL (1) | CL2016002836A1 (pl) |
| CR (1) | CR20160518A (pl) |
| DK (1) | DK3143025T3 (pl) |
| EA (2) | EA035068B1 (pl) |
| ES (2) | ES2949660T3 (pl) |
| FR (1) | FR21C1039I2 (pl) |
| HR (2) | HRP20230637T1 (pl) |
| HU (2) | HUE046491T2 (pl) |
| IL (2) | IL248653B (pl) |
| LT (1) | LTPA2021010I1 (pl) |
| MA (2) | MA51988A (pl) |
| MX (1) | MX371050B (pl) |
| MY (1) | MY174284A (pl) |
| NL (1) | NL301128I2 (pl) |
| NO (1) | NO2021035I1 (pl) |
| NZ (1) | NZ725008A (pl) |
| PE (1) | PE20170128A1 (pl) |
| PH (1) | PH12016502081A1 (pl) |
| PL (2) | PL3143025T3 (pl) |
| PT (1) | PT3143025T (pl) |
| RS (1) | RS59718B1 (pl) |
| SG (1) | SG11201609497TA (pl) |
| SI (2) | SI3663296T1 (pl) |
| TW (1) | TWI667239B (pl) |
| UA (1) | UA119670C2 (pl) |
| WO (1) | WO2015173181A1 (pl) |
| ZA (1) | ZA201607026B (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201813877T4 (tr) | 2012-02-10 | 2018-11-21 | Hoffmann La Roche | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| US10882868B2 (en) * | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| WO2016196386A1 (en) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| JP2018533594A (ja) * | 2015-11-12 | 2018-11-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 筋萎縮性側索硬化症を処置するための化合物 |
| WO2017080967A1 (en) * | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| LT3386511T (lt) | 2015-12-10 | 2021-08-25 | Ptc Therapeutics, Inc. | Hantingtono ligos gydymo būdai |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| EA201991309A1 (ru) * | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| EP3645121A4 (en) | 2017-06-28 | 2021-03-17 | PTC Therapeutics, Inc. | HUNTINGTON'S DISEASE TREATMENT METHODS |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| SG11202002610TA (en) * | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| AU2018344402A1 (en) * | 2017-10-03 | 2020-04-09 | F. Hoffmann-La Roche Ag | New treatment of SMA |
| US20210009590A1 (en) | 2018-03-27 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP3814357B1 (en) | 2018-06-27 | 2024-05-01 | PTC Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020079203A1 (en) | 2018-10-19 | 2020-04-23 | F. Hoffmann-La Roche Ag | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
| CN113966219A (zh) | 2019-06-12 | 2022-01-21 | 豪夫迈·罗氏有限公司 | Sma的新治疗方法 |
| US20220315607A1 (en) | 2019-07-31 | 2022-10-06 | Teva Pharmaceuticals International Gmbh | Solid state forms of risdiplam and process for preparation thereof |
| WO2022048675A1 (zh) * | 2020-09-07 | 2022-03-10 | 苏州科睿思制药有限公司 | Risdiplam晶型及其制备方法和用途 |
| WO2022162107A1 (en) | 2021-02-01 | 2022-08-04 | Sandoz Ag | Crystalline form of risdiplam |
| KR20230157367A (ko) | 2021-03-17 | 2023-11-16 | 에프. 호프만-라 로슈 아게 | 신규 티아졸로피리미디논 유도체 |
| CN116981673A (zh) * | 2021-03-17 | 2023-10-31 | 豪夫迈·罗氏有限公司 | 新颖噻二唑并嘧啶酮衍生物 |
| CA3210678A1 (en) | 2021-03-18 | 2022-09-22 | F. Hoffmann-La Roche Ag | Novel process |
| WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024081932A1 (en) | 2022-10-14 | 2024-04-18 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3345021B2 (ja) * | 1996-08-06 | 2002-11-18 | ファイザー インク． | 置換ピリド―またはピリミド―含有６，６―または６，７―二環式誘導体 |
| CA2700841A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| KR20100012134A (ko) | 2008-07-28 | 2010-02-08 | 신호열 | 마우스 |
| WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| JP2011529722A (ja) * | 2008-08-14 | 2011-12-15 | カーディアック ペースメイカーズ， インコーポレイテッド | 音響通信リンクの性能評価および適合 |
| BR112014016287B1 (pt) * | 2011-12-30 | 2022-08-09 | F. Hoffmann - La Roche Ag | Composto e composição farmacêutica |
| TR201813877T4 (tr) * | 2012-02-10 | 2018-11-21 | Hoffmann La Roche | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. |
| AU2013289938A1 (en) | 2012-07-13 | 2015-01-29 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| WO2017080967A1 (en) | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
-
2015
- 2015-05-11 HR HRP20230637TT patent/HRP20230637T1/hr unknown
- 2015-05-11 ES ES19200058T patent/ES2949660T3/es active Active
- 2015-05-11 ES ES15721701T patent/ES2761423T3/es active Active
- 2015-05-11 PT PT157217019T patent/PT3143025T/pt unknown
- 2015-05-11 KR KR1020167034983A patent/KR102213740B1/ko active IP Right Grant
- 2015-05-11 MA MA051988A patent/MA51988A/fr unknown
- 2015-05-11 PL PL15721701T patent/PL3143025T3/pl unknown
- 2015-05-11 PE PE2016002128A patent/PE20170128A1/es unknown
- 2015-05-11 SI SI201531952T patent/SI3663296T1/sl unknown
- 2015-05-11 MA MA39995A patent/MA39995B1/fr unknown
- 2015-05-11 PL PL19200058.6T patent/PL3663296T3/pl unknown
- 2015-05-11 MX MX2016014547A patent/MX371050B/es active IP Right Grant
- 2015-05-11 HU HUE15721701A patent/HUE046491T2/hu unknown
- 2015-05-11 WO PCT/EP2015/060343 patent/WO2015173181A1/en active Application Filing
- 2015-05-11 CA CA2948561A patent/CA2948561C/en active Active
- 2015-05-11 EA EA201692280A patent/EA035068B1/ru active Protection Beyond IP Right Term
- 2015-05-11 SG SG11201609497TA patent/SG11201609497TA/en unknown
- 2015-05-11 SI SI201531021T patent/SI3143025T1/sl unknown
- 2015-05-11 KR KR1020217002966A patent/KR102256013B1/ko active IP Right Grant
- 2015-05-11 CN CN201580027306.9A patent/CN106459092B/zh active Active
- 2015-05-11 EP EP19200058.6A patent/EP3663296B1/en active Active
- 2015-05-11 MY MYPI2016001903A patent/MY174284A/en unknown
- 2015-05-11 AU AU2015261046A patent/AU2015261046C1/en active Active
- 2015-05-11 RS RS20191541A patent/RS59718B1/sr unknown
- 2015-05-11 DK DK15721701T patent/DK3143025T3/da active
- 2015-05-11 EP EP23169721.0A patent/EP4241772A3/en active Pending
- 2015-05-11 EP EP15721701.9A patent/EP3143025B1/en active Active
- 2015-05-11 UA UAA201612716A patent/UA119670C2/uk unknown
- 2015-05-11 CR CR20160518A patent/CR20160518A/es unknown
- 2015-05-11 EA EA202090486A patent/EA202090486A3/ru unknown
- 2015-05-11 NZ NZ72500815A patent/NZ725008A/en unknown
- 2015-05-11 JP JP2016567816A patent/JP6236173B2/ja active Active
- 2015-05-14 TW TW104115433A patent/TWI667239B/zh active
- 2015-05-14 AR ARP150101500A patent/AR100442A1/es not_active Application Discontinuation
-
2016
- 2016-10-12 ZA ZA2016/07026A patent/ZA201607026B/en unknown
- 2016-10-19 PH PH12016502081A patent/PH12016502081A1/en unknown
- 2016-10-31 IL IL24865316A patent/IL248653B/en active IP Right Grant
- 2016-11-08 CL CL2016002836A patent/CL2016002836A1/es unknown
- 2016-11-14 US US15/351,267 patent/US9969754B2/en active Active
-
2019
- 2019-10-17 IL IL270027A patent/IL270027B/en active IP Right Grant
- 2019-11-29 HR HRP20192159TT patent/HRP20192159T1/hr unknown
-
2021
- 2021-09-09 FR FR21C1039C patent/FR21C1039I2/fr active Active
- 2021-09-10 NO NO2021035C patent/NO2021035I1/no unknown
- 2021-09-14 HU HUS2100037C patent/HUS2100037I1/hu unknown
- 2021-09-14 LT LTPA2021010C patent/LTPA2021010I1/lt unknown
- 2021-09-15 NL NL301128C patent/NL301128I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100037I1 (hu) | Vegyületek gerinc eredetû izomsorvadás kezelésére | |
| HK1256089A1 (zh) | 用於治療脊髓性肌萎縮的組合物 | |
| HK1215399A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
| HK1246784A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
| HK1258823A1 (zh) | 用於治療肌營養不良的方法 | |
| HK1231359A1 (zh) | 用於畸形矯正的矯形器 | |
| HK1244217A1 (zh) | 用於治療蛋白質病的方法 | |
| EP3354288C0 (en) | STERILIZATION DEVICE | |
| IL251790B (en) | Compounds include thiazole for the treatment of culture diseases | |
| PL3160913T3 (pl) | Sposób oczyszczania osadu biologicznego | |
| GB201405132D0 (en) | Fixation apparatus | |
| GB201715519D0 (en) | Hand treatment apparatus | |
| HK1248130A1 (zh) | 用於治療疼痛的組合物 | |
| IL231816A (en) | Bone fracture treatment devices | |
| GB2534681B (en) | Treatment apparatus | |
| GB201604658D0 (en) | Treatment for pain | |
| PT3250218T (pt) | Péptido natkide para o tratamento da obesidade | |
| ZA201800752B (en) | Improved prosthesis for osteosynthesis | |
| ZA201607027B (en) | Method for treating or enhancing muscle tissue | |
| PL3129031T3 (pl) | Kompozycja do terapii zaburzeń żołądkowych | |
| PL3194551T3 (pl) | Stała kompozycja do traktowania tekstyliów | |
| GB201507044D0 (en) | Waste treatment | |
| GB201505205D0 (en) | Treatment for pain | |
| GB201504688D0 (en) | Treatment for pain | |
| GB201418676D0 (en) | Compounds for use |